OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc. (OKUR), a clinical-stage biopharmaceutical company, reported a net loss of $59.5M for FY 2025 ended December 31, 2025, up 13% from $52.7M in FY 2024, driven by higher operating expenses of $63.0M versus $54.4M prior year. No revenue was generated as the company advances its lead candidate OKI-219 in Phase 1 PIKture-01 trial for PI3Kα H1047R-mutated breast cancer, with data expected in 2026. Research and development expenses rose 10% to $48.3M from $43.8M, reflecting increased personnel costs and clinical activities. General and administrative expenses increased 39% to $14.7M from $10.6M, due to higher share-based compensation and public company costs post-Merger. Balance sheet shows total assets of $62.1M, including $59.0M cash, down from $114.9M prior year. Stockholders' equity stands at $56.2M. Operating cash use was $51.8M, with cash runway into Q4 2026. Going concern doubt persists due to capital needs for clinical advancement. Strategic focus remains on mutant-selective PI3Kα inhibitors, with pan-mutant candidate announcement planned Q1 2026.

Key Takeaways